Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Federal Trade Commission
McKesson
Covington
Cipla
AstraZeneca
Farmers Insurance
US Army
Johnson and Johnson
Medtronic

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,618,172

« Back to Dashboard

Which drugs does patent 8,618,172 protect, and when does it expire?

Patent 8,618,172 protects TEKTURNA HCT and is included in one NDA.

This patent has thirty patent family members in twenty-four countries.
Summary for Patent: 8,618,172
Title:Galenical formulations of organic compounds
Abstract: The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of HCTZ and a hydrophilic filler selected from the group a carbohydrate or combinations thereof, e.g. sugars, sugar alcohols and starches or combinations of these.
Inventor(s): Willmann; Matthias (Basel, CH)
Assignee: Novartis AG (Basel, CH)
Application Number:12/304,244
Patent Claim Types:
see list of patent claims
Compound; Dosage form;

Drugs Protected by US Patent 8,618,172

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Noden Pharma TEKTURNA HCT aliskiren hemifumarate; hydrochlorothiazide TABLET;ORAL 022107-001 Jan 18, 2008 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Noden Pharma TEKTURNA HCT aliskiren hemifumarate; hydrochlorothiazide TABLET;ORAL 022107-002 Jan 18, 2008 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Noden Pharma TEKTURNA HCT aliskiren hemifumarate; hydrochlorothiazide TABLET;ORAL 022107-003 Jan 18, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Noden Pharma TEKTURNA HCT aliskiren hemifumarate; hydrochlorothiazide TABLET;ORAL 022107-004 Jan 18, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,618,172

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0612540.5Jun 23, 2006
PCT Information
PCT FiledJune 21, 2007PCT Application Number:PCT/EP2007/005476
PCT Publication Date:December 27, 2007PCT Publication Number: WO2007/147596

International Patents Family Members for US Patent 8,618,172

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation 2009101971 ➤ Sign Up
Peru 09902012 ➤ Sign Up
Peru 03732008 ➤ Sign Up
New Zealand 572937 ➤ Sign Up
Norway 20090262 ➤ Sign Up
Malaysia 146779 ➤ Sign Up
Mexico 2008016533 ➤ Sign Up
Morocco 30527 ➤ Sign Up
South Korea 101442272 ➤ Sign Up
South Korea 20090021353 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Healthtrust
Cipla
Federal Trade Commission
Chubb
Medtronic
Citi
Julphar
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot